We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • Alpine Immune and AbbVie sign $865m immunology deal pharmaceutical-technology
    June 22, 2020
    Clinical-stage immunotherapy firm Alpine Immune Sciences and biopharmaceutical company AbbVie have signed an option and license agreement potentially worth $805m, for ALPN-101 drug.
PharmaSources Customer Service